Federal Circuit: Proposed Generic Drug Does Not Meet Patent Limitations

(February 13, 2017, 10:51 AM EST) -- WASHINGTON, D.C. — A Florida federal judge erred in concluding that an abbreviated new drug application (ANDA) satisfies various Markush group requirements set forth in claim 1(b) of a drug composition patent, the Federal Circuit U.S. Court of Appeals ruled Feb. 10 (Shire Development LLC, et al. v. Watson Pharmaceuticals Inc., et al., No. 16-1785, Fed. Cir., 2017 U.S. App. LEXIS 2393)....

Attached Documents

Related Sections